Toledo-Ramírez MI, Romero-Feregrino R, Reyes-Gómez U, Luévanos-Velázquez A, Reyes-Hernández KL, Reyes-Hernández MU, Reyes-Hernández DP, López-Cruz G, Pérez-Pacheco O

Language: Spanish
References: 26
Page: 136-143
PDF size: 306.78 Kb.

ABSTRACT

Anaphylaxis is a life-threatening condition that can occur due to type 1 hypersensitivity. It occurs when an antigen is found in circulating IgE produced by previous exposure that results in the activation and degradation of mast cells and basophils, causing the release of chemical mediators.
We report a case of a 6-year-old boy who, after applying the booster dose of the MMR vaccine, presents a severe anaphylactic reaction that warrants endotracheal intubation and ventilatory support. In his laboratory studies, his immunoglobulins were reported to be normal in IgE, or that ruled out a congenital immunodeficiency, its evolution was to the improvement with the multidisciplinary management.
Anaphylactic reactions secondary to MMR are extremely rare and are attributed to the measles fraction. Adrenaline is the most effective drug for the treatment of anaphylaxis because of its ability to prevent or reverse bronchospasm and cardiovascular collapse. A close observation is always required regarding the application of the viral triple vaccine and counts in all the units with drugs for the immediate use of severe reactions.

REFERENCES

1. Kwong KY, Maalouf N, Jones CA. Urticaria and angiodemea pathophysiology, diagnosis and treatment Pediatr Ann 1998; 27: 719-24.

2. Johansson GS, T. Bieber T, Dahl R, Friedmann SP, Lanier QB, Lockey RF. A revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of World Allergy Organization J. Allergy Clin Immunol. 2004; 113: 832-6.

3. Panesar SS, Javad S, de Silva D, Nwaru BI, Hickstein L, Muraro A, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013; 68:1353–61.

4. Wood RA, Camargo CA, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014; 133: 461–7.

5. Decker WW, Campbell RL, Manivannan V. The etiology and incidence of anaphylaxis in Rochester, Minnesota A. report from the Rochester Epidemiology Project J Allergy Clin Inmunol 2008; 122: 280-4.

6. Kagy L, Blaiss MS. Anaphylaxis in children Pediatr Ann 1998; 27: 727-34.

7. Mejía EM, Suárez JT, Arreola A, Alonso D, Estrada A, Zamora CA. Y cols. Neumonitis por hipersensibilidad Neumología y Cirugía de Tórax 2007; 66(3): 115-23.

8. Muraro A, Roberts G, Clark A, Eigenmann AP, Halken S, Lack G. The management of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology Allergy. 2007; 62: 857-71.

9. Cardona DV. Guía de actuación en anafilaxia Guideline for the management of anaphylaxis Grupo de trabajo de la Guía GALAXIA de actuación en anafilaxia ◊ Med Clin 2011; 136: 349-55 - DOI: 10.1016/j.medcli.2010.10.003

10. Sampson A, Muñoz FA, Campbell LR, Adkinson JrFN, Bock AS, Branum A. Second symposium on the definition and management of anaphylaxis: summary report-- Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium J Allergy Clin Immunol. 2006; 117: 391-397.

11. Echeverría ZL, del Olmo MR, Santana RC. Anafilaxia en Pediatría. Protoc Diagn Ter Pediatr. 2013; 1: 63- 80.

12. Pérez VS, Gutiérrez GM, Rodríguez GM, Díez DJ, Puig BJ, Gomar FJ, Alguacil RC. Sospecha de reacciones adversas a la vacuna triple vírica notificadas al Centro de Farmacovigilancia de la Comunidad Valenciana An Pediatr (Barc). 2013;78(5):297---302.

13. https://autismodiario.org/2013/05/14/autismo-vacunas- neuroinflamacion-toxicos-y-aspectos-relacionados/

14. https://www.healthychildren.org/English/health-issues/ injuries-emergencies/Pages/How-to-Use-an-Epinephrine- Auto-Injector.aspx

15. Macías PM, López CE, Cardoso HG, Barrón PR. Enfermedad diseminada fatal por vacuna BCG en un paciente con inmunodeficiencia combinada severa Acta Ped. Mex. 2006; 27(3): 145-50.

16. American Academy of Pediatrics Anafilaxia Medicina de emergencias pediátricas quinta edición al español. USA. 2015.p. 56-8.

17. Guía técnica Vacunación del niño alérgico Asturias España 2011-Klein NP, Lewis E, Fireman B, et al. Safety of Measles-containing vaccines in 1-year-old Children. Pediatrics 2015;135(2):e321-e329.

18. Mei ST, Ewe JT, Chee PH, et al. Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necesary? Med J Malasya 2016;71(4):157-60.

19. Tuncela T , Sancaklib O, Ozdogrub E. Administración satisfactoria de la vacuna triple viral mediante una prueba de provocación gradual en una paciente con anafilaxia después de una vacunación previa Arch Argent Pediatr 2017;115(2):e89-e91 / e89

20. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 2009;64(2):204-12.

21. Simons EF. First-aid treatment of anaphylaxis to food: Focus on epinephrine J Allergy Clin Immunol. 2004; 113: 837.

22. Brown AS. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis Curr Opin Allergy Clin Immunol. 2005; 5: 359.

23. Actualización en las recomendaciones del tratamiento del choque anafiláctico: novedades sobre el uso de adrenalina Arch Argent Pediatr 2015;113(1): 81-7.

24. Echeverría Zudaire LA, del Olmo de la Lama MR, Santana Rodríguez C. Anafilaxia en Pediatría. Protoc Diagn Ter Pediatr. 2013;1:63-80.

25. Sheikh A, Broek TV, Brown GS, Simons FE. H(1)-antihistamines for the treatment of anaphylaxis: Cochrane systematic review Allergy 2007; 62: 830-7.

26. Rowe HB, C. Spooner C, Ducharme MF, Bretzlaff AJ, Bota WG Early emergency department treatment of acute asthma with systemic corticosteroids Cochrane Database Syst Rev. 2001; 1: CD002178.